-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since the beginning of this year, the Chinese medicine industry has frequently issued heavy support policies
.
For example, in February, the State Council issued the "Several Policy Measures on Accelerating the Development of Traditional Chinese Medicine with Characteristics"; on June 30, the National Health Commission and other ministries jointly formulated the "Opinions on Further Strengthening the Work of Traditional Chinese Medicine in General Hospitals to Promote the Coordinated Development of Traditional Chinese and Western Medicine"; On July 7, the five departments jointly formulated the "Implementation Plan for the Communication of Chinese Medicine Culture (2021-2025)"
.
The industry generally believes that under the influence of a series of favorable policies, the development of the Chinese medicine industry has obviously begun to accelerate
.
Among them, in terms of innovative drugs, according to incomplete statistics, 11 innovative Chinese medicines have been approved since 2021.
The approved new drugs are widely distributed in the field of disease treatment, covering multiple fields such as respiratory, neurological, and digestive
.
In addition, as of mid-December, the number of new TCM drug registrations in 2021 has also exceeded 58 (accepted numbers, the same below), which is an increase of 114.
81% compared to 2020; whether it is for clinical application or application for marketing , Each set a record high of 48 and 10 respectively
.
Among them, category 1 innovative drugs accounted for 86.
21% of the total new TCM drugs, including 36 category 1.
1 new drugs, 10 category 1.
2 new drugs, and 4 category 1.
3 drugs
.
From a performance perspective, as of the third quarter of 2021, the Chinese medicine sector has also achieved operating income of 248.
85 billion yuan, an increase of 11.
31% year-on-year; net profit attributable to the parent company has reached 26.
26 billion yuan, an increase of 20.
79% year-on-year
.
Analysts pointed out that, on the whole, the reason why the market size of China's traditional Chinese medicine industry can continue to grow at a high speed is mainly due to the support and guidance of favorable domestic policies and the Have responded
.
With the help of these policies, it is expected that in the future, a large number of relevant companies will continue to inherit the essence, maintain integrity and innovate, usher in a larger market space, and move towards a higher-quality development path
.
It is worth noting that some people in the industry have also pointed out that with the continuous introduction of my country’s policies to support Chinese medicine, the structure of the Chinese medicine industry will gradually be optimized, and the valuation of the sector is expected to be restored.
.
In fact, due to the strong support and promotion of the development of Chinese medicine by the state and the continuous expansion of market demand for Chinese medicine, the Chinese medicine sector has been strengthening frequently since the beginning of this year
.
For example, after the opening of the A-share Chinese medicine sector, the daily limit of Dali Pharmaceutical, Magic Pharmaceutical, Teyi Pharmaceutical, Taiji Group, Hongri Pharmaceutical and other stocks rose very obviously after the opening of the market
.
Among them, Longjin Pharmaceutical has a daily limit of 4 consecutive boards
.
Specifically, as of the noon closing on the 27th, the stock reported 11.
02 yuan per share, with a turnover of 137 million yuan.
In the past week, the cumulative increase in the stock has exceeded 50%
.
In the future, with the support of a series of favorable policies, the pace of development of Chinese medicine will continue to accelerate
.
But at the same time, the Chinese medicine industry also urgently needs to break the bottleneck of focusing on sales rather than R&D, weak overall competitiveness, and insufficient corporate innovation vitality
.
Especially in the context of medical insurance control fees, the industry believes that Chinese medicine companies urgently need to accelerate their transformation and upgrading in order to accelerate the development of the Chinese medicine industry in a high-quality direction and help the entire industry usher in more opportunities
.
.
For example, in February, the State Council issued the "Several Policy Measures on Accelerating the Development of Traditional Chinese Medicine with Characteristics"; on June 30, the National Health Commission and other ministries jointly formulated the "Opinions on Further Strengthening the Work of Traditional Chinese Medicine in General Hospitals to Promote the Coordinated Development of Traditional Chinese and Western Medicine"; On July 7, the five departments jointly formulated the "Implementation Plan for the Communication of Chinese Medicine Culture (2021-2025)"
.
The industry generally believes that under the influence of a series of favorable policies, the development of the Chinese medicine industry has obviously begun to accelerate
.
Among them, in terms of innovative drugs, according to incomplete statistics, 11 innovative Chinese medicines have been approved since 2021.
The approved new drugs are widely distributed in the field of disease treatment, covering multiple fields such as respiratory, neurological, and digestive
.
In addition, as of mid-December, the number of new TCM drug registrations in 2021 has also exceeded 58 (accepted numbers, the same below), which is an increase of 114.
81% compared to 2020; whether it is for clinical application or application for marketing , Each set a record high of 48 and 10 respectively
.
Among them, category 1 innovative drugs accounted for 86.
21% of the total new TCM drugs, including 36 category 1.
1 new drugs, 10 category 1.
2 new drugs, and 4 category 1.
3 drugs
.
From a performance perspective, as of the third quarter of 2021, the Chinese medicine sector has also achieved operating income of 248.
85 billion yuan, an increase of 11.
31% year-on-year; net profit attributable to the parent company has reached 26.
26 billion yuan, an increase of 20.
79% year-on-year
.
Analysts pointed out that, on the whole, the reason why the market size of China's traditional Chinese medicine industry can continue to grow at a high speed is mainly due to the support and guidance of favorable domestic policies and the Have responded
.
With the help of these policies, it is expected that in the future, a large number of relevant companies will continue to inherit the essence, maintain integrity and innovate, usher in a larger market space, and move towards a higher-quality development path
.
It is worth noting that some people in the industry have also pointed out that with the continuous introduction of my country’s policies to support Chinese medicine, the structure of the Chinese medicine industry will gradually be optimized, and the valuation of the sector is expected to be restored.
.
In fact, due to the strong support and promotion of the development of Chinese medicine by the state and the continuous expansion of market demand for Chinese medicine, the Chinese medicine sector has been strengthening frequently since the beginning of this year
.
For example, after the opening of the A-share Chinese medicine sector, the daily limit of Dali Pharmaceutical, Magic Pharmaceutical, Teyi Pharmaceutical, Taiji Group, Hongri Pharmaceutical and other stocks rose very obviously after the opening of the market
.
Among them, Longjin Pharmaceutical has a daily limit of 4 consecutive boards
.
Specifically, as of the noon closing on the 27th, the stock reported 11.
02 yuan per share, with a turnover of 137 million yuan.
In the past week, the cumulative increase in the stock has exceeded 50%
.
In the future, with the support of a series of favorable policies, the pace of development of Chinese medicine will continue to accelerate
.
But at the same time, the Chinese medicine industry also urgently needs to break the bottleneck of focusing on sales rather than R&D, weak overall competitiveness, and insufficient corporate innovation vitality
.
Especially in the context of medical insurance control fees, the industry believes that Chinese medicine companies urgently need to accelerate their transformation and upgrading in order to accelerate the development of the Chinese medicine industry in a high-quality direction and help the entire industry usher in more opportunities
.
